Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8455565
Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions
granted -
US 8454977
Non-toxic biofilm inhibitor
granted -
US 8454958
Methods for detecting and inhibiting angiogenesis
granted -
US 8450062
SOCS-3 promoter methylation in cancer
granted -
US 8450471
TAL effector-mediated DNA modification
granted -
US 8450278
MUC18 targeting peptides
granted -
US 8449875
Targeting pseudotyped retroviral vectors
granted -
US 8450481
Compounds for inhibiting protein aggregation, and methods for making and using them
granted -
US 8445021
Functionalized magnetic nanoparticles and methods of use thereof
granted -
US 8445507
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
granted -
US 8445588
Hydrophilic copolymers and assemblies containing the same
granted -
US 8445632
Selective poly-N-substituted glycine antibiotics
granted -
US 8445473
Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
granted -
US 8445491
Wnt protein signalling inhibitors
granted -
US 8445254
Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety
granted -
US 8444991
Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
granted -
US 8440168
Image-guided therapy of myocardial disease: composition, manufacturing and applications
granted -
US 8440832
Heterocyclic modulators of cannabinoid receptors
granted -
US 8440811
DNA nanostructures that promote cell-cell interaction and use thereof
granted -
US 8440636
Micro-RNA family that modulates fibrosis and uses thereof
granted -
US 8440432
Tal effector-mediated DNA modification
granted -
US 8440431
TAL effector-mediated DNA modification
granted -
US 8440205
Streptococcal C5A peptidase vaccine
granted -
US 8440208
Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease
granted -
US 8440182
Methods and compositions for treating phenylketonuria
granted -
US 8440229
Hollow silica nanospheres and methods of making same
granted -
US 8440460
Methods for transdifferentiating cells
granted -
US 8440621
Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
granted -
US 8435943
Protein stabilization formulations
granted -
US 8435533
Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia
granted -
US 8435941
Mini-hepcidin peptides and methods of using thereof
granted -
US 8435570
Nitrite formulations and their use as nitric oxide prodrugs
granted -
US 8431558
Compositions and methods for modification of biomolecules
granted -
US 8431626
Disulfide monomers comprising ethylenically unsaturated norbornyl groups suitable for dental compositions
granted -
US 8431561
Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
granted -
US 8430832
Selective cytopheresis devices and related methods thereof
granted -
US 8425446
Selective cytopheresis devices and related methods
granted -
US 8426365
Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
granted -
US 8425445
Selective cytopheresis devices and related methods thereof
granted -
US 8425930
Prebiotic oligosaccharides
granted -
US 8426188
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
granted -
US 8425447
Selective cytopheresis devices and related methods thereof
granted -
US 8420612
Diabetes treatment methods and drug targets therefor
granted -
US 8420885
Determining the capability of a test compound to affect solid tumor stem cells
granted -
US 8420852
Phospholipase A2 inhibitors and their use in treating neurological injury and disease
granted -
US 8420678
Small molecule inhibitors of the pleckstrin homology domain and methods for using same
granted -
US 8420118
Anionic lipids and lipid nano-structures and methods of producing and using same
granted -
US 8420619
Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory